DD on Wei-Ping Min (Pt 1)
Post# of 5066
Posted On: 08/07/2013 4:35:52 PM
Here is some DD on Dr. Min
This is copied from London Health Sciences Centre in Ontario, Canada. This page gives a brief description of the scientists in the Multiple-Organ Transplant Team. It certainly touts him quite well! The link is also posted below:
http://www.lhsc.on.ca/Research_Training/MOTP/.../index.htm
research focus is transplant immunology. Specifically, his research is looking at interfering with the processing of RNA (also called ‘RNA interference’, RNAi). This is an advanced technology with the potential to stop several disease processes including cancer, autoimmune diseases as well as transplant rejection by silencing gene expression. This is due to the specificity and potency of gene silencing that can be achieved through RNAi as well as avoiding potentially toxic drugs. Dr. Min’s laboratory is the first in the world to apply RNAi to immunomodulation and immunotherapy related to transplantation. By developing and optimizing tissue/cell-specific targeting methods to deliver siRNA, he hopes to develop novel targeted RNAi therapies to prevent tissue injury and graft rejection with the eventual goal of establishing immune tolerance.
This is copied from London Health Sciences Centre in Ontario, Canada. This page gives a brief description of the scientists in the Multiple-Organ Transplant Team. It certainly touts him quite well! The link is also posted below:
http://www.lhsc.on.ca/Research_Training/MOTP/.../index.htm
research focus is transplant immunology. Specifically, his research is looking at interfering with the processing of RNA (also called ‘RNA interference’, RNAi). This is an advanced technology with the potential to stop several disease processes including cancer, autoimmune diseases as well as transplant rejection by silencing gene expression. This is due to the specificity and potency of gene silencing that can be achieved through RNAi as well as avoiding potentially toxic drugs. Dr. Min’s laboratory is the first in the world to apply RNAi to immunomodulation and immunotherapy related to transplantation. By developing and optimizing tissue/cell-specific targeting methods to deliver siRNA, he hopes to develop novel targeted RNAi therapies to prevent tissue injury and graft rejection with the eventual goal of establishing immune tolerance.
(0)
(0)RIVULET MEDIA INC. (RIVU) Stock Research Links
Scroll down for more posts ▼